Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: A 56-week, randomized, double blind, phase 3 study (PRESS XII study)

Manjunath Krishnappa, Kishor Patil, Krupi Parmar, Purav Trivedi, Nirali Mody, Chintan Shah, Khushboo Faldu, Sanjay Maroo, Piyush Desai, Kamlesh Fatania, Satyanarayan Murthy, R. Balamurugan, Manish Agarwal, K. P. Singh, G. S. Kalra, Vipul Khandelwal, Ashish Singwala, Hemant Thacker, Rahul Tulle, Harish RaoMukund Kumbla, Parminder Singh, Ashok Khatri, Sumit Agrawal, R. N. Sarkar, Dinesh Agarwal, Girish Bhatia, R. P. Agarwal, Surender Kumar, P. R. Vamsi Krishna, Ajay Kumar Ajmani, Amit Asalkar, Indraneel Basu, Sudip Chatterjee, Vinod Kumar Pavithran, Rupam Das, Aniruddha Dharmadhikari, Vikram Vardhan, M. Madusudhan Babu, Nilanjan Sengupta, Srirang Abkari, R. Harikrishna, Rashmi Chovatia, Deven Parmar

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: A 56-week, randomized, double blind, phase 3 study (PRESS XII study)'. Together they form a unique fingerprint.

Medicine & Life Sciences